This inventor holds 3 USPTO granted patents. Top assignees: The Mclean Hospital Corporation, University of Rochester, The General Hospital Corporation. Active years: 1993-1997.
Company Filing History:
2 out of 125 
2 out of 994 
1 out of 3,070 
Years Active: 1993-1997
Title: Charles A Marotta: Innovator in Alzheimer's Research
Introduction
Charles A Marotta is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of Alzheimer's disease research, holding a total of 3 patents. His work focuses on innovative methods to combat the effects of amyloid peptides, which are implicated in neurodegenerative diseases.
Latest Patents
One of his latest patents involves the reversal of β/A4 amyloid peptide-induced morphological changes. This invention provides oligonucleotides that inhibit the expression of β/A4 peptide associated with Alzheimer's disease and Down's syndrome. Furthermore, it outlines methods for reversing the morphological changes caused in neuronal cells by the β/A4 peptide. Another significant patent is an in vitro method for screening drugs that inhibit the production of the A4-amyloid peptide. This method involves contacting a drug with a host transformed with a DNA construct that overexpresses the human A4-amyloid peptide, allowing for the detection of drug efficacy in preventing production or increasing degradation of the peptide.
Career Highlights
Throughout his career, Charles has worked with esteemed organizations such as McLean Hospital Corporation and the University of Rochester. His research has been pivotal in advancing our understanding of Alzheimer's disease and potential therapeutic approaches.
Collaborations
Charles has collaborated with notable colleagues, including Sayeeda Zain and Ron Majocha, contributing to a rich environment of innovation and research.
Conclusion
Charles A Marotta's work exemplifies the intersection of innovation and medical research, particularly in the fight against Alzheimer's disease. His patents and collaborations highlight his commitment to advancing scientific knowledge and developing effective treatments.